BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Braveheart Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$19.21+0.50 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $142.19M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Braveheart Bio's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
13 buys · 0 sales
Net bought $159.03M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fhmlsp, L.P. | 4,976,457 | 5.50% | 13G (passive) | Aug 7, 2026 |
| Orbimed Advisors LLC | 12,175,159 | 13.50% | 13D (active) amendment | Sep 8, 2026 |
| AH Bio Fund IV, L.P. | 10,232,420 | 11.40% | 13D (active) | Aug 7, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Travis Murdoch | CEO and President, Director | 8,333,637 | 9.26% | Aug 7, 2026 |
| Michele A. Anderson | Chief Development Officer | 332,161 | 0.37% | Aug 7, 2026 |
| James Paul Rickey | Chief Financial Officer | 703,575 | 0.78% | Aug 7, 2026 |
| Vineeta Agarwala | Director | 10,232,420 | 11.36% | Aug 14, 2026 |
| Erez Chimovits | Director, 10% owner | 273,333 | 0.30% | Aug 11, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 273,333 | 0.30% | Aug 11, 2026 |
| Capital GP IX LLC OrbiMed | Director, 10% owner | – | – | Aug 11, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 1,102,739 | 1.22% | Aug 11, 2026 |
| David Charles Lubner | Director | 55,555 | 0.06% | Aug 7, 2026 |
| Jasper Bos | Director | – | – | Aug 7, 2026 |
| Christopher Viehbacher | Director | 759,857 | 0.84% | Aug 7, 2026 |
| Tim Lohoff | Director | – | – | Aug 7, 2026 |
| David I. Malek | Director | 1,013,297 | 1.13% | Aug 7, 2026 |
| Jason V. Coloma | Director | 1,100,456 | 1.22% | Aug 5, 2026 |
| Marc L. Andreessen | 10% owner | 9,132,420 | 10.14% | Aug 11, 2026 |
| AH Bio Fund IV, L.P. | 10% owner | – | – | Aug 11, 2026 |
| AH Equity Partners Bio IV, L.L.C. | 10% owner | – | – | Aug 11, 2026 |
| Benjamin A. Horowitz | 10% owner | – | – | Aug 11, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | 7,420,091 | 8.24% | Aug 10, 2026 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion | 10% owner | 30,331,502 | 33.69% | Aug 7, 2026 |
| Growth III Management B.V. Forbion | 10% owner | – | – | Aug 7, 2026 |
| Ventures Fund VII Cooperatief U.A. Forbion | 10% owner | – | – | Aug 7, 2026 |
| Ventures VII Management B.V. Forbion | 10% owner | 1,102,737 | 1.22% | Aug 7, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marc L. Andreessen 10% owner | Aug 7, 2026 | Conversion | +9,132,420 | – | – | 9,132,420 |
| Marc L. Andreessen 10% owner | Aug 7, 2026 | Buy | +1,100,000 | $18.00 | $19.80M | 10,232,420 |
| Genesis GP LLC OrbiMed Director, 10% owner | Aug 7, 2026 | Buy | +273,333 | $18.00 | $4.92M | 273,333 |
| Genesis GP LLC OrbiMed Director, 10% owner | Aug 7, 2026 | Conversion | +9,132,420 | – | – | 10,235,159 |
| Genesis GP LLC OrbiMed Director, 10% owner | Aug 7, 2026 | Buy | +1,666,667 | $18.00 | $30.00M | 11,901,826 |
| Erez Chimovits Director, 10% owner | Aug 7, 2026 | Buy | +273,333 | $18.00 | $4.92M | 273,333 |
| Erez Chimovits Director, 10% owner | Aug 7, 2026 | Buy | +1,666,667 | $18.00 | $30.00M | 11,901,826 |
| Erez Chimovits Director, 10% owner | Aug 7, 2026 | Conversion | +9,132,420 | – | – | 10,235,159 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Aug 7, 2026 | Conversion | +7,420,091 | – | – | 7,420,091 |
| James Paul Rickey Chief Financial Officer | Aug 7, 2026 | Buy | +27,777 | $18.00 | $499.99K | 520,927 |
| David I. Malek Director | Aug 7, 2026 | Buy | +4,166 | $18.00 | $74.99K | 533,845 |
| Christopher Viehbacher Director | Aug 7, 2026 | Buy | +83,333 | $18.00 | $1.50M | 609,519 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion 10% owner | Aug 7, 2026 | Conversion | +7,990,867 | – | – | 8,505,478 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion 10% owner | Aug 7, 2026 | Buy | +1,920,000 | $18.00 | $34.56M | 11,640,546 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion 10% owner | Aug 7, 2026 | Buy | +1,680,000 | $18.00 | $30.24M | 10,185,478 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion 10% owner | Aug 7, 2026 | Conversion | +9,132,420 | – | – | 9,720,546 |
| Travis Murdoch CEO and President, Director | Aug 7, 2026 | Buy | +83,333 | $18.00 | $1.50M | 2,940,670 |
| David Charles Lubner Director | Aug 7, 2026 | Buy | +55,555 | $18.00 | $999.99K | 55,555 |
| Michele A. Anderson Chief Development Officer | Aug 7, 2026 | Buy | +1,111 | $18.00 | $20.00K | 332,161 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.